StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Monopar Therapeutics (MNPR)

Tue, 02 Jun 2026 06:58:04 -0400

H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating and $105.00 price target on Monopar Therapeutics (NASDAQ: MNPR).

The analyst commented: "At EASL 2026, Monopar presented 48-week longitudinal data for ALXN1840 in Wilson disease, reinforcing its potential as the first meaningful therapeutic advance for these patients in decades. The Phase 2 open-label trial evaluating ALXN1840 monotherapy in heavily pre-treated patients compared liver biopsies performed at baseline and at week 48 to assess liver pathology stabilization and improvement. At Week 48, ALXN1840 demonstrated a broadly favorable profile across histologic, neurologic, and patient-reported endpoints in Wilson disease. Among the 24 patients with

Monopar presents Phase 2 data showing ALXN1840 benefits for Wilson disease

Mon, 01 Jun 2026 07:00:52 -0400

Monopar Therapeutics Inc. (NASDAQ: MNPR) presented Phase 2 trial data for ALXN1840 at the European Association for the Study of the Liver Congress 2026, showing liver disease stabilization and neurological improvements in Wilson disease patients.

The open-label, multicenter Phase 2 trial evaluated ALXN1840 over 48 weeks in 29 treatment-experienced Wilson disease patients who had received standard care for a median duration of 13.8 years. Wilson disease is a genetic condition caused by ATP7B gene mutations that impairs the body's ability to remove excess copper.

Among 24 patients with paired liver biopsies, the majority demonstrated stabilization or improvement across liver measures at Week

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026

Mon, 01 Jun 2026 07:00:00 -0400

WILMETTE, Ill., June 01, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the presentation (link) of Phase 2 ALXN1840-WD-205 data at the European Association for the Study of the Liver (EASL) Congress 2026. In a presentation titled “ALXN1840 (tiomolibdate choline) Stabilizes Liver Disease and Improves Neurological Symptoms as well as Quality of Life in Treatment-Experienced Wilson Disease Patients,” lead author Valentina Medici, MD, Professor of Medicine at the University of California Davis, presented results

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026

Mon, 01 Jun 2026 07:00:00 -0400

Form 8-K Monopar Therapeutics For: May 29

Fri, 29 May 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260529/26576205.html

Form 8-K Monopar Therapeutics For: May 29

Fri, 29 May 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260529/26576205.html

Monopar study shows ALXN1840 improves copper balance in Wilson disease

Tue, 19 May 2026 17:33:11 -0400

Monopar Therapeutics Inc. (NASDAQ: MNPR) announced that Hepatology Communications published results from a Phase 2 study of ALXN1840 (tiomolibdate choline) in Wilson disease patients. The open-label trial demonstrated statistically significant improvements in daily copper balance.

The study evaluated nine Wilson disease patients across two centers in the United Kingdom and New Zealand. Participants received daily ALXN1840 dosing while on a copper-controlled diet, with researchers measuring copper intake and output during baseline and treatment periods.

Key results showed a cumulative mean decrease in copper balance of -6.08 mg over 21 days compared to baseline. Daily copper balance changed by -0.37 mg during the

Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease

Tue, 19 May 2026 17:33:00 -0400

WILMETTE, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that Hepatology Communications has published a peer-reviewed manuscript entitled “Effect of Tiomolibdate Choline on Copper Balance in Patients with Wilson Disease: an Open-label Phase 2 Trial.”

The publication, which can be found at (link), reports results from the Phase 2 ALXN1840-WD-204 study (NCT04573309) and demonstrates that ALXN1840 (tiomolibdate choline) produces a rapid, statistically significant, and sustained improvement in daily copper balance

Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease

Tue, 19 May 2026 17:33:00 -0400

Form 8-K Monopar Therapeutics For: May 19

Tue, 19 May 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260519/26522738.html

Form 8-K Monopar Therapeutics For: May 19

Tue, 19 May 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260519/26522738.html

Form SCHEDULE 13G Monopar Therapeutics Filed by: Saturn V Capital Management LP

Fri, 15 May 2026 13:26:00 -0400

si-local-file:///var/storage/secattach/20260515/26503294.html

Form SCHEDULE 13G Monopar Therapeutics Filed by: Saturn V Capital Management LP

Fri, 15 May 2026 13:26:00 -0400

si-local-file:///var/storage/secattach/20260515/26503294.html

Monopar Therapeutics (MNPR) Misses Q1 EPS by 46c

Fri, 15 May 2026 06:12:21 -0400

Monopar Therapeutics (NASDAQ: MNPR) reported Q1 EPS of ($0.46).

For earnings history and earnings-related data on Monopar Therapeutics (MNPR) click here.

Form 10-Q Monopar Therapeutics For: Mar 31

Thu, 14 May 2026 14:01:00 -0400

si-local-file:///var/storage/secattach/20260514/26493474.html

Form 10-Q Monopar Therapeutics For: Mar 31

Thu, 14 May 2026 14:01:00 -0400

si-local-file:///var/storage/secattach/20260514/26493474.html

Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Thu, 14 May 2026 14:00:00 -0400

WILMETTE, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced first quarter 2026 financial results and provided business updates.